{"id":36469,"date":"2025-08-01T16:44:40","date_gmt":"2025-08-01T13:44:40","guid":{"rendered":"https:\/\/massivebio.com\/?p=36469"},"modified":"2025-09-22T09:52:09","modified_gmt":"2025-09-22T06:52:09","slug":"understanding-the-different-types-of-myelofibrosis-primary-vs-secondary","status":"publish","type":"post","link":"https:\/\/massivebio.com\/understanding-the-different-types-of-myelofibrosis-primary-vs-secondary\/","title":{"rendered":"Understanding the Different Types of Myelofibrosis: Primary vs. Secondary"},"content":{"rendered":"<section class=\"l-section wpb_row height_small\"><div class=\"l-section-h i-cf\"><div class=\"g-cols vc_row via_grid cols_1 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><p><span style=\"font-weight: 400;\">Myelofibrosis is an uncommon yet serious chronic blood cancer that disrupts the bone marrow\u2019s capacity to produce healthy blood cells. This condition is part of the myeloproliferative neoplasms (MPNs), a set of disorders defined by excessive blood cell growth. While the condition is often grouped under one name, it actually comes in more than one form. Understanding the types of myelofibrosis, especially the distinction between<\/span><b> primary vs secondary myelofibrosis<\/b><span style=\"font-weight: 400;\">, is essential for accurate diagnosis, prognosis, and treatment.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">There are two <\/span><b>types of myelofibrosis<\/b><span style=\"font-weight: 400;\">-primary and secondary-with the latter commonly developing as a progression from essential thrombocythemia (ET) or polycythemia vera (PV). Understanding what happens when the disease progresses to its most aggressive phase, the blast phase, is crucial. This guide offers clarity on the key differences between these types and their implications for disease management, serving as a valuable resource for patients, caregivers, and medical professionals alike.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">What Is Myelofibrosis?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Myelofibrosis is a bone marrow cancer characterized by scarring (fibrosis) that impairs the production of healthy red blood cells, white blood cells, and platelets. As a result, patients may experience symptoms such as anemia, fatigue, night sweats, enlarged spleen (splenomegaly), and a high risk of bleeding or infection. The question: <\/span><a href=\"https:\/\/massivebio.com\/what-is-myelofibrosis-and-affect-the-body\/\"><span style=\"font-weight: 400;\">What is myelofibrosis and affect the body?<\/span><\/a><span style=\"font-weight: 400;\"> very critical.\u00a0\u00a0\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">There are two main types of myelofibrosis:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Primary Myelofibrosis (PMF)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/massivebio.com\/secondary-myelofibrosis\/\"><span style=\"font-weight: 400;\">Secondary Myelofibrosis <\/span><\/a><span style=\"font-weight: 400;\">(SMF)<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">An in-depth look at each form reveals important distinctions.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">What Is Primary Myelofibrosis and How Does It Develop Without a Precursor?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Primary myelofibrosis is a form of chronic myeloproliferative neoplasm that arises on its own, without evolving from a pre-existing blood disorder. This disease, classified as a chronic myeloproliferative neoplasm, is frequently tied to mutations in the JAK2, CALR, or MPL genes.<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">Key Features of Primary Myelofibrosis:<\/span><\/h3>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Develops independently, not from another condition.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Most commonly occurs in people aged 50 and above.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Some patients are symptom-free at first, while others present with fatigue, anemia, and spleen enlargement.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Over time, bone marrow becomes increasingly fibrotic, impairing normal blood cell production.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">May progress to <\/span><b>blast phase primary myelofibrosis<\/b><span style=\"font-weight: 400;\">, an aggressive form resembling acute leukemia.<\/span><\/li>\n<\/ul>\n<h3><span style=\"font-weight: 400;\">Blast Phase Primary Myelofibrosis<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">In the blast phase, the disease transforms into an acute leukemia-like state, typically marked by 20% or more blast cells in the blood or bone marrow. This phase is associated with:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Severe anemia and thrombocytopenia<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Rapidly worsening symptoms<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Poor prognosis and limited <\/span><a href=\"https:\/\/massivebio.com\/treatment-myelofibrosis\/\"><span style=\"font-weight: 400;\">myelofibrosis treatment<\/span><\/a><span style=\"font-weight: 400;\"> options<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Because of its serious nature, blast phase primary myelofibrosis requires immediate medical intervention, often involving chemotherapy or stem cell transplantation if the patient is eligible.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">What Is Secondary Myelofibrosis and How Does It Relate to Other MPNs?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Secondary myelofibrosis develops as a complication of pre-existing myeloproliferative neoplasms, most commonly evolving from essential thrombocythemia (ET) or polycythemia vera (PV). In most cases, it evolves from either:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Essential Thrombocythemia (ET)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Polycythemia Vera (PV)<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">In both situations, chronic overstimulation of the bone marrow eventually leads to scarring and a decline in healthy blood cell production, resulting in post-ET or post-PV myelofibrosis.<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">Post Essential Thrombocythemia Myelofibrosis<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Essential thrombocythemia is characterized by an overproduction of platelets. In some patients, this can slowly transition into<\/span><b> post essential thrombocythemia myelofibrosis<\/b><span style=\"font-weight: 400;\">, which includes:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Worsening anemia<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Enlargement of the spleen and liver<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Increased marrow fibrosis<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Possible evolution to blast phase, though usually more slowly than in primary myelofibrosis<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Patients with post-ET myelofibrosis are typically monitored closely for early signs of progression, such as increased white blood cell count, fatigue, or new-onset bone pain.<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">Polycythemia Vera-Associated Myelofibrosis<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">The disease results in the body generating too many red blood cells. Over time, the increased cellular activity and stress on the marrow can cause fibrosis, leading to <\/span><b>post polycythemia vera myelofibrosis<\/b><span style=\"font-weight: 400;\">. Common signs of progression include:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Rapid drop in hemoglobin levels<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Significant weight loss<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Elevated white blood cells<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Massive splenomegaly<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Both post-ET and post-PV myelofibrosis fall under the broader umbrella of <\/span><b>secondary myelofibrosis<\/b><span style=\"font-weight: 400;\">, and their treatment is often guided by how far the disease has progressed and the patient\u2019s risk score.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">What Is the Difference Between Primary and Secondary Myelofibrosis?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">The key difference is that <\/span><b>primary myelofibrosis<\/b><span style=\"font-weight: 400;\"> arises on its own, while secondary myelofibrosis develops from a pre-existing myeloproliferative neoplasm such as essential thrombocythemia or polycythemia vera. The distinction between primary vs secondary myelofibrosis lies primarily in disease origin:<\/span><\/p>\n<table>\n<tbody>\n<tr>\n<td><b>Feature<\/b><\/td>\n<td><b>Primary Myelofibrosis<\/b><\/td>\n<td><b>Secondary Myelofibrosis<\/b><\/td>\n<\/tr>\n<tr>\n<td><b>Origin<\/b><\/td>\n<td><span style=\"font-weight: 400;\">Arises spontaneously<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Evolves from ET (Essential Thrombocythemia) or PV (Polycythemia Vera)<\/span><\/td>\n<\/tr>\n<tr>\n<td><b>Common Genetic Mutations<\/b><\/td>\n<td><span style=\"font-weight: 400;\">JAK2, CALR, MPL<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Same mutations possible, sometimes additional abnormalities<\/span><\/td>\n<\/tr>\n<tr>\n<td><b>Typical Onset<\/b><\/td>\n<td><span style=\"font-weight: 400;\">Later in life<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Can occur in patients with long-term ET or PV<\/span><\/td>\n<\/tr>\n<tr>\n<td><b>Risk of Blast Phase<\/b><\/td>\n<td><span style=\"font-weight: 400;\">Present, sometimes more aggressive<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Present, may develop more gradually<\/span><\/td>\n<\/tr>\n<tr>\n<td><b>Treatment Goals<\/b><\/td>\n<td><span style=\"font-weight: 400;\">Manage symptoms, slow progression<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Same, plus monitoring of transformation from original MPN<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">Understanding this difference is crucial because it helps clinicians determine prognosis, treatment approach, and frequency of monitoring. Patients with secondary myelofibrosis often have a known medical history that provides clues to how the disease might behave.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">How Is Myelofibrosis Diagnosed, Monitored, and Treated?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Myelofibrosis, whether primary or secondary, is typically diagnosed through a combination of blood tests (such as CBC, LDH, and peripheral smear), bone marrow biopsy, and molecular testing to identify specific mutations. Imaging studies may also be used to assess disease severity and help guide treatment decisions.<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">Risk Stratification<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Doctors use risk scoring systems such as DIPSS, IPSS, and MYSEC-PM to classify myelofibrosis severity and determine the next steps.<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">Treatment Options<\/span><\/h3>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Observation (for low-risk or asymptomatic patients)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">JAK inhibitors (like ruxolitinib or fedratinib) to control symptoms and spleen size<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Anemia treatments, including blood transfusions or erythropoiesis-stimulating agents<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Stem cell transplant (for high-risk or blast phase disease, in eligible patients)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Clinical trials, especially for those with aggressive forms or rare mutations<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Management plans differ significantly depending on whether a patient has primary myelofibrosis, post essential thrombocythemia myelofibrosis, or post polycythemia vera myelofibrosis.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">Why Is It Important to Understand the Different Types of Myelofibrosis?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Understanding the distinctions between primary and secondary myelofibrosis helps improve patient care, guide treatment choices, and support long-term disease management. While both forms lead to similar complications, their origins, risk levels, and progression patterns differ. That\u2019s why personalized care is essential.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">If you or a loved one has been diagnosed with primary myelofibrosis, post essential thrombocythemia myelofibrosis, or post polycythemia vera myelofibrosis, don\u2019t hesitate to ask your healthcare team about:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Mutation analysis results<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Your disease risk category<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Signs to watch for (like worsening anemia or spleen enlargement)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Treatment goals: symptom relief vs. disease modification<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Knowledge is power. And when it comes to a complex disease like myelofibrosis, the more you understand your specific subtype, the better prepared you are to navigate the journey ahead. Massive Bio empowers patients at every stage of cancer with personalized care and AI-driven solutions.<\/span><\/p>\n<p><a href=\"https:\/\/www.frontiersin.org\/journals\/hematology\/articles\/10.3389\/frhem.2024.1356561\/full\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">https:\/\/www.frontiersin.org\/journals\/hematology\/articles\/10.3389\/frhem.2024.1356561\/full<\/span><\/a><\/p>\n<p><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6245993\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6245993\/<\/span><\/a><span style=\"font-weight: 400;\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/ashpublications.org\/blood\/article\/132\/22\/2339\/107700\/How-I-treat-the-blast-phase-of-Philadelphia\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">https:\/\/ashpublications.org\/blood\/article\/132\/22\/2339\/107700\/How-I-treat-the-blast-phase-of-Philadelphia<\/span><\/a><span style=\"font-weight: 400;\">\u00a0<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/section>\n","protected":false},"excerpt":{"rendered":"Myelofibrosis is an uncommon yet serious chronic blood cancer that disrupts the bone marrow\u2019s capacity to produce healthy blood cells. This condition is part of the myeloproliferative neoplasms (MPNs), a set of disorders defined by excessive blood cell growth. While the condition is often grouped under one name, it actually comes in more than one...","protected":false},"author":11,"featured_media":36449,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[57],"tags":[],"class_list":["post-36469","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.6 (Yoast SEO v26.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Understanding the Different Types of Myelofibrosis: Primary vs. Secondary<\/title>\n<meta name=\"description\" content=\"Myelofibrosis is an uncommon yet serious chronic blood cancer that disrupts the bone marrow\u2019s capacity to produce healthy blood cells.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/massivebio.com\/understanding-the-different-types-of-myelofibrosis-primary-vs-secondary\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Understanding the Different Types of Myelofibrosis: Primary vs. Secondary %\" \/>\n<meta property=\"og:description\" content=\"Myelofibrosis is an uncommon yet serious chronic blood cancer that disrupts the bone marrow\u2019s capacity to produce healthy blood cells.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/massivebio.com\/understanding-the-different-types-of-myelofibrosis-primary-vs-secondary\/\" \/>\n<meta property=\"og:site_name\" content=\"Massive Bio\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/facebook.com\/people\/Massive-Bio-As\/100094663612187\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-01T13:44:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-22T06:52:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/08\/Understanding-the-Different-Types-of-Myelofibrosis_-Primary-vs.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"767\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sinan Gul\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MassiveBio\" \/>\n<meta name=\"twitter:site\" content=\"@MassiveBio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sinan Gul\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Understanding the Different Types of Myelofibrosis: Primary vs. Secondary","description":"Myelofibrosis is an uncommon yet serious chronic blood cancer that disrupts the bone marrow\u2019s capacity to produce healthy blood cells.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/massivebio.com\/understanding-the-different-types-of-myelofibrosis-primary-vs-secondary\/","og_locale":"en_US","og_type":"article","og_title":"Understanding the Different Types of Myelofibrosis: Primary vs. Secondary %","og_description":"Myelofibrosis is an uncommon yet serious chronic blood cancer that disrupts the bone marrow\u2019s capacity to produce healthy blood cells.","og_url":"https:\/\/massivebio.com\/understanding-the-different-types-of-myelofibrosis-primary-vs-secondary\/","og_site_name":"Massive Bio","article_publisher":"https:\/\/facebook.com\/people\/Massive-Bio-As\/100094663612187\/","article_published_time":"2025-08-01T13:44:40+00:00","article_modified_time":"2025-09-22T06:52:09+00:00","og_image":[{"width":1024,"height":767,"url":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/08\/Understanding-the-Different-Types-of-Myelofibrosis_-Primary-vs.webp","type":"image\/webp"}],"author":"Sinan Gul","twitter_card":"summary_large_image","twitter_creator":"@MassiveBio","twitter_site":"@MassiveBio","twitter_misc":{"Written by":"Sinan Gul","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/massivebio.com\/understanding-the-different-types-of-myelofibrosis-primary-vs-secondary\/#article","isPartOf":{"@id":"https:\/\/massivebio.com\/understanding-the-different-types-of-myelofibrosis-primary-vs-secondary\/"},"author":{"name":"Sinan Gul","@id":"https:\/\/massivebio.com\/#\/schema\/person\/961d749445523a588f7ffb7086d037c6"},"headline":"Understanding the Different Types of Myelofibrosis: Primary vs. Secondary","datePublished":"2025-08-01T13:44:40+00:00","dateModified":"2025-09-22T06:52:09+00:00","mainEntityOfPage":{"@id":"https:\/\/massivebio.com\/understanding-the-different-types-of-myelofibrosis-primary-vs-secondary\/"},"wordCount":1152,"commentCount":4,"publisher":{"@id":"https:\/\/massivebio.com\/#organization"},"image":{"@id":"https:\/\/massivebio.com\/understanding-the-different-types-of-myelofibrosis-primary-vs-secondary\/#primaryimage"},"thumbnailUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/08\/Understanding-the-Different-Types-of-Myelofibrosis_-Primary-vs.webp","articleSection":["Blog"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/massivebio.com\/understanding-the-different-types-of-myelofibrosis-primary-vs-secondary\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/massivebio.com\/understanding-the-different-types-of-myelofibrosis-primary-vs-secondary\/","url":"https:\/\/massivebio.com\/understanding-the-different-types-of-myelofibrosis-primary-vs-secondary\/","name":"Understanding the Different Types of Myelofibrosis: Primary vs. Secondary","isPartOf":{"@id":"https:\/\/massivebio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/massivebio.com\/understanding-the-different-types-of-myelofibrosis-primary-vs-secondary\/#primaryimage"},"image":{"@id":"https:\/\/massivebio.com\/understanding-the-different-types-of-myelofibrosis-primary-vs-secondary\/#primaryimage"},"thumbnailUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/08\/Understanding-the-Different-Types-of-Myelofibrosis_-Primary-vs.webp","datePublished":"2025-08-01T13:44:40+00:00","dateModified":"2025-09-22T06:52:09+00:00","description":"Myelofibrosis is an uncommon yet serious chronic blood cancer that disrupts the bone marrow\u2019s capacity to produce healthy blood cells.","breadcrumb":{"@id":"https:\/\/massivebio.com\/understanding-the-different-types-of-myelofibrosis-primary-vs-secondary\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/massivebio.com\/understanding-the-different-types-of-myelofibrosis-primary-vs-secondary\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/massivebio.com\/understanding-the-different-types-of-myelofibrosis-primary-vs-secondary\/#primaryimage","url":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/08\/Understanding-the-Different-Types-of-Myelofibrosis_-Primary-vs.webp","contentUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/08\/Understanding-the-Different-Types-of-Myelofibrosis_-Primary-vs.webp","width":1024,"height":767,"caption":"Understanding the Different Types of Myelofibrosis: Primary vs. Secondary"},{"@type":"BreadcrumbList","@id":"https:\/\/massivebio.com\/understanding-the-different-types-of-myelofibrosis-primary-vs-secondary\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Homepage","item":"https:\/\/massivebio.com\/"},{"@type":"ListItem","position":2,"name":"Blog","item":"https:\/\/massivebio.com\/blog-en\/"},{"@type":"ListItem","position":3,"name":"Understanding the Different Types of Myelofibrosis: Primary vs. Secondary"}]},{"@type":"WebSite","@id":"https:\/\/massivebio.com\/#website","url":"https:\/\/massivebio.com\/","name":"Cancer Analysis and Clinical Trial Matching","description":"Best Oncology Advisory Services By Cancer Treatment Care Specialists &amp; Tumor Board Experts in America","publisher":{"@id":"https:\/\/massivebio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/massivebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/massivebio.com\/#organization","name":"Massive Bio","url":"https:\/\/massivebio.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/massivebio.com\/#\/schema\/logo\/image\/","url":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/01\/Massive-Bio-Logo-Circle.svg","contentUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/01\/Massive-Bio-Logo-Circle.svg","width":"1024","height":"1024","caption":"Massive Bio"},"image":{"@id":"https:\/\/massivebio.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/facebook.com\/people\/Massive-Bio-As\/100094663612187\/","https:\/\/x.com\/MassiveBio","https:\/\/instagram.com\/massive_bio\/","https:\/\/tiktok.com\/@massivebio","https:\/\/youtube.com\/massivebio"],"email":"support@massivebio.com","legalName":"Massive Bio"},{"@type":"Person","@id":"https:\/\/massivebio.com\/#\/schema\/person\/961d749445523a588f7ffb7086d037c6","name":"Sinan Gul"}]}},"_links":{"self":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts\/36469","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/comments?post=36469"}],"version-history":[{"count":4,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts\/36469\/revisions"}],"predecessor-version":[{"id":36473,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts\/36469\/revisions\/36473"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/media\/36449"}],"wp:attachment":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/media?parent=36469"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/categories?post=36469"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/tags?post=36469"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}